Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Core Laboratories (NYSE:CLB) by 23.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,956 shares of the oil and gas company’s stock after purchasing an additional 557 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Core Laboratories were worth $320,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Robeco Institutional Asset Management B.V. boosted its stake in Core Laboratories by 60.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 1,096 shares of the oil and gas company’s stock worth $120,000 after buying an additional 414 shares in the last quarter. Captrust Financial Advisors purchased a new stake in Core Laboratories in the fourth quarter worth approximately $139,000. Teachers Advisors LLC boosted its stake in Core Laboratories by 56.6% in the fourth quarter. Teachers Advisors LLC now owns 1,779 shares of the oil and gas company’s stock worth $195,000 after buying an additional 643 shares in the last quarter. Callahan Advisors LLC purchased a new stake in Core Laboratories in the fourth quarter worth approximately $201,000. Finally, Regal Investment Advisors LLC purchased a new stake in Core Laboratories in the fourth quarter worth approximately $205,000.
Shares of CLB stock opened at $127.31 on Monday. The company has a quick ratio of 1.76, a current ratio of 2.11 and a debt-to-equity ratio of 1.55. Core Laboratories has a fifty-two week low of $86.55 and a fifty-two week high of $130.34. The company has a market capitalization of $5.63 billion, a price-to-earnings ratio of 63.66 and a beta of 1.38.
Core Laboratories (NYSE:CLB) last announced its quarterly earnings data on Wednesday, April 25th. The oil and gas company reported $0.57 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.57. Core Laboratories had a return on equity of 62.69% and a net margin of 13.24%. The firm had revenue of $170.00 million during the quarter, compared to the consensus estimate of $171.03 million. During the same quarter in the previous year, the company posted $0.42 earnings per share. The business’s revenue was up 8.6% on a year-over-year basis. equities analysts predict that Core Laboratories will post 2.71 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 22nd. Shareholders of record on Friday, April 27th will be given a $0.55 dividend. The ex-dividend date of this dividend is Thursday, April 26th. This represents a $2.20 annualized dividend and a yield of 1.73%. Core Laboratories’s payout ratio is currently 110.00%.
Several analysts have issued reports on the company. ValuEngine raised Core Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday. Zacks Investment Research lowered Core Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, May 16th. Citigroup upped their target price on Core Laboratories from $117.00 to $123.00 and gave the stock a “neutral” rating in a research note on Monday, April 30th. Cowen set a $98.00 target price on Core Laboratories and gave the stock a “hold” rating in a research note on Friday, April 13th. Finally, Credit Suisse Group assumed coverage on Core Laboratories in a research note on Thursday, March 15th. They issued an “outperform” rating and a $107.94 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $115.63.
About Core Laboratories
Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.
Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.